Alder BioPharmaceuticals Inc (ALDR) 銘柄情報

Hummm

big volume past few days

whats going on here?

POW POW BOOM

Dropping fast Offering Coming !

The offering is expected to close on July 18, 2017

The offering is expected to close on July 18, 2017

Great Short Here $9.40 Offering coming !

9k out today

The price to the public in the Offering is $10.00 per share, and the Underwriters have agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $9.40 per share

* * $ALDR Video Chart 07-13-17 * *

Link to Video - click here to watch the technical chart video

Almost ready to buy. Many thanks to the overreactors!!!

Hope it goes under 11. Pick up some dxtr, and monitoring dcth for a buy in.

https://seekingalpha.com/article/4084528-alder-phase-3-migraine-data-points-major-issues

out at 13.80 thanks ald

good trade what do you think it will do

I sold that same day for $15, which was way too early

took 13.70 long for a trade

In at $14 for the bounce

Valuation analyses show Alder Biopharmaceuticals is highly undervalued... Earnings today to be the catalyst?


Analysis

Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine

https://finance.yahoo.com/news/alder-reports-positive-top-line-120000216.html

Investor 100

ALDR @ Stockcharts

Like the RSI..MACD..MFI..heading higher closing in on 200MA



Investor 100

Nice 6% gainer today!!!

Going much higher!

Investor 100

Alder Presents Preclinical Data for ALD1613 at ENDO 2016

-ALD1613 Administration Reduces Plasma Corticosterone in Multiple Preclinical Models-

http://finance.yahoo.com/news/alder-presents-preclinical-data-ald1613-171500565.html

Key Points:

In vitro, ALD1613 inhibits ACTH-induced cortisol secretion in a mouse adrenal cell line.
ALD1613 administration in rats with artificially elevated ACTH and corticosterone levels resulted in a rapid and durable reduction of plasma corticosterone levels.
In non-human primates, ALD1613 demonstrated stable and durable reductions in plasma cortisol levels by >50%.

Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder, said, “Existing therapeutic options for patients with congenital adrenal hyperplasia and Cushing's disease comprise treatments that provide limited disease control and involve significant side effects. We believe these limitations indicate a clear need for new therapies such as ALD1613, which targets ACTH to diminish the overproduction of cortisol. The data presented today demonstrate the capacity of ALD1613 to reduce corticosteroid levels in preclinical settings. We intend to use these studies as part of an IND filing that we plan to submit to the FDA in the second half of 2016.”

Investor 100

Our March highlight just gained 50%: Alder Biopharmaceuticals

http://marketexclusive.com/our-march-highlight-just-gained-50-alder-biopharmaceuticals-inc-nasdaqaldr/4872/

http://finance.yahoo.com/news/alder-reports-phase-2b-trial-110000104.html

Monster Run On Huge News Up 57%

http://seekingalpha.com/news/3169667-alder-bios-migraine-candidate-ald403-successful-mid-stage-study-shares-9-percent-premarket


Investor 100

Alder is a Risky Allocation in a Crowded, but Rewarding Space

http://marketexclusive.com/alder-is-a-risky-allocation-in-a-crowded-but-rewarding-space/2587/

Cramer @ ALDR

Looking forward to the Phase 3 results!

Buying the dip as well...

http://www.thestreet.com/story/13393479/1/jim-cramer-s-top-takeaways-alder-biopharmaceuticals-ensco.html?puc=yahoo&cm_ven=YAHOO
Alder BioPharmaceuticals (ALDR) : For his "Executive Decision" segment, Cramer spoke with Dr. Randall Schatzman, president and CEO of Alder BioPharmaceuticals, a stock that rallied over 11% in today's session but still remains 48% from its 2015 highs.

Schatzman said while it's been a wild week on Wall Street, the biopharmaceutical space has never been stronger. There is more innovation and more drugs being approved than ever.

When asked about his company's migraine treatment, which is currently in Phase III testing, Schatzman said the company believes it has identified and neutralized one of the primary factors that trigger migraines. So far, patients are responding well in the study. He said Alder has been successful using social media to spread the word to the 36 million migraine sufferers out there.

Schatzman was also upbeat on his company's arthritis drug, which will be entering Phase III trials soon.

Cramer said the best time to buy these stocks is when they're hated, not when they're loved.

ALDR @ Stockcharts

Like the risk opportunity and MFI indicator!



Investor 100

ALDR @ JPMorgan Healthcare Conference Presentation

http://files.shareholder.com/downloads/AMDA-2K5VML/1355915823x0x869777/F50353BF-AD37-4358-9D66-D4B10F92ADC6/JPM_2016_Presentation_Present_FINAL.pdf

Investor 100

Migraine Statistics

In the U.S., more than 37 million people suffer from migraines. Some migraine studies estimate that 13 percent of adults in the U.S. population have migraines, and 2-3 million migraine suffers are chronic.

Almost 5 million in the U.S. experience at least one migraine attack per month, while more than 11 million people blame migraines for causing moderate to severe disability.

One study estimates the loss of productivity in the U.S. to be between $5.6 billion to $17.2 billion per year because of missed work. The average migraine sufferer misses two days of work per year. Some who suffer from persistent migraines work during a migraine attack, which they say lowers productivity. It is estimated that migraines are the reason for 36 million days of bed rest, plus 21.5 million days of restricted activity.


https://migraine.com/migraine-statistics/

Investor 100

CEO @ ALDR Interview

Like the story here with ALDR!



Investor 100

CEO @ Mad Money

CEO provided some guidance in 2016 on Mad Money last evening that I think was positive news ( Migrane - Phase 3 )....like the tone and opportunity here!

Investor 100

ALDR @ Stockcharts



Investor 100

Here is What Hedge Funds Think About Alder Biopharmaceuticals Inc (ALDR)

heck yes...doubled up my position on the dip!

Is Alder Biopharmaceuticals Inc (NASDAQ:ALDR) a buy here? Money managers are taking a bullish view. The number of bullish hedge fund positions went up by 5 recently. ALDR was in 23 hedge funds’ portfolios at the end of September. There were 18 hedge funds in our database with ALDR holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks.

Investor 100


http://www.insidermonkey.com/blog/here-is-what-hedge-funds-think-about-alder-biopharmaceuticals-inc-aldr-392542/

ALDR @ Stockcharts

Like to movement and indicators..bought the dip..moving much higher!



http://www.thestreet.com/video/13317423/migraine-drug-results-will-cure-stock-headache-says-alder-ceo.html?puc=yahoov&cm_ven=YAHOOV

Investor 100

ALDR

Bought the dips ....



Investor 100

ALDR @ Stockcharts

Adding a few more shares on this dip!



Accumulating shares...

Investor 100

Moving Up @ ALDR

Added a few more shares on the dip!




Investor 100

Upward @ ALDR

Nice bounce today with a 2.37% gain!

Investor 100

Dip @ ALDR

Like the dip...bought a few more shares!

Investor 100

Upward @ ALDR

LIke the 2.59% gainer today...buying on dips...

Investor 100

Steady @ ALDR

Solid 8.63 gainer today...glad I bought the dip!



Investor 100

Added @ ALDR

Added a few nore shares on the dip!

Investor 100

Steady @ ALDR

More room for growth with a 1.61% gain!

http://www.alderbio.com/therapeutics/pipeline/

http://www.thestreet.com/story/13176848/1/jim-cramer-says-alder-biopharmaceuticals-aldr-is-meeting-gigantic-unmet-needs.html



Investor 100

Zacks @ ALDR

Alder Biopharmaceuticals Inc. (ALDR) in Focus: Stock Soars 12.9% - Tale of the Tape
http://finance.yahoo.com/news/alder-biopharmaceuticals-inc-aldr-focus-131801881.html

Investor 100

Stockcharts @ ALDR

Took a few more shares on the dip...nice 1.8% gain today in a choppy market.



Investor 100

Upward @ ALDR

Solid 12% gainer today...added on the dip...much higher!



Investor 100

Stock Issue @ ALDR

I was concered with this news but the fact of the matter is the stock is up afterwards and today when the market was down 35) points this stock was up over 2.85%!

Alder Biopharmaceuticals (ALDR) Stock Rises After Pricing Secondary Offering
http://www.thestreet.com/story/13200800/1/alder-biopharmaceuticals-aldr-stock-rises-after-pricing-secondary-offering.html?puc=yahoo&cm_ven=YAHOO

Investor 100

Stockcharts @ ALDR

One of the few stock up today however any dip I will add more shares.

I beleive this company is coming up with a Migrane solution - best in class!



Investor 100

Added @ ALDR

Nice dip to add more shares- like the story and CEO interview on CNBC!

Alder BioPharmaceuticals Announces Commencement of Public Offering of Common Stock
http://finance.yahoo.com/news/alder-biopharmaceuticals-announces-commencement-public-200100715.html

Upward @ ALDR

Buying more on the dip!

Alder Bio Up As Credit Suisse Lauds Migraine Drug
http://news.investors.com/062415-758806-aldr-stock-hits-high-on-credit-suisse-report.htm?ven=yahoocp&src=aurlled&ven=yahoo



Investor 100